Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term continuation study of Myozyme in infantile-onset Pompe disease after Protocol AGLU01602
2005-001629-27Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2005
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of alglucosidase alfa in Pompe disease (2 arms), sponsored by Sanofi. Primary endpoint: Alive and free of invasive ventilatory support. Started Jun 2005; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2005-001629-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001629-27.